Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel

Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label